Announcements Trials
Browse Landscape

Status

Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 3Expanded_access 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gastrointestinal 1Endocrine 1Breast 1

Conditions

Thyroid Cancer, Papillary 1Pancreatic Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Medullary 1Breast Neoplasms 1

Interventions

veliparib 2tucatinib 2leronlimab 2abemaciclib 2Trastuzumab 2Capecitabine 2Alpelisib 2zenocutuzumab 1selpercatinib 1sacituzumab govitecan 1ribociclib 1pertuzumab 1pegilodecakin 1palbociclib 1margetuximab 1iniparib 1glembatumumab vedotin 1gedatolisib 1eribulin 1Vinorelbine 1Proton Pump Inhibitors 1Letrozole 1Lapatinib 1Hydrocortisone 1Everolimus 1Cisplatin 1Ado-Trastuzumab Emtansine 1AM0010 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × selpercatinib × Breast × Clear all
NCT03906331 2025-01-17

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

Eli Lilly and Company

Approved for marketing
BreastEndocrineGastrointestinalHead & NeckThoracic

Thyroid Cancer, Papillary, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Pancreatic Neoplasms, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡